Top of the morning to you, and a fine one it is. Once again, clear blue skies and cool breezes are enveloping the Pharmalot campus, where the short person is hovering over a laptop and the fast-growing official mascot is unsuccessfully chasing squirrels. As for us, we are engaged in our usual ritual of heating the coffee kettle to concoct cups of stimulation. Once again, we are enjoying glazed doughnut. One can never be too sweet, yes? Meanwhile, here are some items of interest for you. Have a smashing day and do keep in touch. …

Moncef Slaoui, a venture capitalist and a former GlaxoSmithKline (GSK) executive who was tapped to lead the Trump administration Covid-19 vaccine effort, has spent the last several days trying to disentangle his stock portfolio and his intricate ties to pharmaceutical interests, The New York Times reports. But some ethics and financial securities experts voiced concerns about the arrangement he struck with the administration. In agreeing to accept the position, Slaoui did not come on board as a government employee, but on a contract, receiving $1 for his service.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy